GCGR

GCGR is the class B GPCR that mediates glucagon's counter-regulatory response to hypoglycemia - driving hepatic glycogenolysis and gluconeogenesis to raise blood glucose. It is overactivated in type 2 diabetes, where chronically elevated glucagon contributes to fasting hyperglycemia. GCGR antagonism lowers blood glucose without causing hypoglycemia, and GCGR/GLP-1R dual or triple agonism is the structural foundation of the most advanced obesity/metabolic drugs currently in development. Every scaffold targeting glucose homeostasis, obesity, or NASH that involves glucagon signaling routes through this card.

Receptor structure and signaling

GCGR (chromosome 17q25.3, 477 aa) adopts the canonical class B architecture: ~100-aa extracellular domain (ECD) with α-β-β-α fold and a conserved disulfide, connected via a short stalk to seven TM helices. Glucagon (29 aa, derived from proglucagon in pancreatic alpha cells) engages via the two-domain mechanism: C-terminal glucagon helix docks to the ECD first, then the N-terminal segment inserts into the TM bundle to drive activation. Key TM contacts: Gln232^{3.37} H-bonds the glucagon N-terminus; Trp304^{5.36}, Tyr239^{3.44}, and Phe365^{6.56} provide hydrophobic caging. Activation drives TM6 outward 0.4–1+ nm via the PxxG hinge. Primary coupling: Gs → adenylyl cyclase → cAMP → PKA → CREB → glycogenolysis and gluconeogenesis in liver. β-Arrestin 1 terminates signaling via tail-engaged phosphoinositide-bridged binding. Biased agonists exist: N-terminal modifications (des-His¹, Phe¹) reduce β-arrestin recruitment while prolonging cAMP. GCGR binds glucagon 100-fold more selectively than GLP-1R. Oxyntomodulin (a proglucagon-derived GCGR/GLP-1R co-agonist) has 10–100-fold lower GCGR potency than glucagon. GCGR is highly expressed in liver (40-fold over other tissues), kidney, heart, and adipose.

Clinical pipeline and research scaffolds

No pure GCGR antagonist is approved. MK-0893, LY2409021, and similar small molecules were tested in Phase 2 for T2D and showed HbA1c reduction but raised LDL and aminotransferases. Cotadutide (GCGR/GLP-1R dual agonist) is in Phase 3 for NASH and obesity. Tirzepatide (GIP/GLP-1 dual agonist, approved) structurally informs triple agonist design. Mazdutide and pemvidutide (GLP-1/GCGR) are in Phase 2/3 trials. For peptide research, the tractable recipes are: glucagon analogs with stabilized α-helices (Aib substitutions, lactam bridges) for extended half-life; GCGR/GLP-1R dual peptide agonists using glucagon/GLP-1 chimera scaffolds (oxyntomodulin framework) to tune receptor selectivity ratios; biased GCGR agonists that maximize cAMP over β-arrestin to sustain hepatic glucose output for hypoglycemia rescue; and GCGR N-terminal truncation series to define the minimal pharmacophore for ligand design.